Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$1.48	$1.48	$0.63 ▼ $1.51	$60.83M	1.25	621,691 shs	N/A
ADCT ADC Therapeutics	$3.10 +11.9%	$1.56	$1.05 ▼ $4.13	$307.45M	1.54	610,748 shs	953,749 shs
CRVS Corvus Pharmaceuticals	$3.80	$3.40	$1.75 ▼ $10.00	$259.04M	0.67	733,897 shs	509,024 shs
TVGN Tevogen Bio	$1.29 -4.1%	$1.09	$0.26 ▼ $3.09	$236.30M	-0.82	5.03 million shs	1.60 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	+7.25%	+60.87%
ADCT ADC Therapeutics	0.00%	+28.36%	+114.53%	+94.36%	-9.62%
CRVS Corvus Pharmaceuticals	0.00%	+8.88%	+4.97%	-3.80%	+75.93%
TVGN Tevogen Bio	0.00%	-1.91%	+27.23%	+8.90%	+59.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ADCT ADC Therapeutics	2.4022 of 5 stars	3.5	2.0	0.0	0.0	3.8	0.8	0.6
CRVS Corvus Pharmaceuticals	2.1964 of 5 stars	3.5	1.0	0.0	0.0	2.4	2.5	0.6
TVGN Tevogen Bio	3.9619 of 5 stars	3.5	4.0	0.0	0.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	0.00	N/A	N/A	N/A
ADCT ADC Therapeutics	3.00	Buy	$7.75	150.00% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	294.74% Upside
TVGN Tevogen Bio	3.00	Buy	$7.10	452.53% Upside

Current Analyst Ratings Breakdown

Latest ACHL, TVGN, ADCT, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/12/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
4/29/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/21/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/31/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $7.00
3/31/2025	ADCT ADC Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/26/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$14.00 ➝ $15.00
3/26/2025	CRVS Corvus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
ADCT ADC Therapeutics	$75.82M	4.06	N/A	N/A	($1.93) per share	-1.61
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($1.10) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.65	N/A	N/A	N/A	N/A	-54.45%	-47.68%	8/12/2025 (Estimated)
ADCT ADC Therapeutics	-$240.05M	-$1.45	N/A	N/A	N/A	-300.00%	N/A	-61.33%	8/5/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$27.03M	-$0.98	N/A	N/A	N/A	N/A	-70.71%	-45.90%	8/12/2025 (Estimated)
TVGN Tevogen Bio	-$70K	N/A	0.00	∞	N/A	N/A	-396.07%	749.97%	N/A

Latest ACHL, TVGN, ADCT, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
3/27/2025	Q4 2024	ADCT ADC Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$19.01 million	$19.00 million
3/25/2025	Q4 2024	CRVS Corvus Pharmaceuticals	-$0.12	-$0.18	-$0.06	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	6.04	6.04
ADCT ADC Therapeutics	N/A	4.92	4.68
CRVS Corvus Pharmaceuticals	N/A	0.92	0.92
TVGN Tevogen Bio	N/A	0.34	0.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
ADCT ADC Therapeutics	41.10%
CRVS Corvus Pharmaceuticals	46.64%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
ADCT ADC Therapeutics	4.10%
CRVS Corvus Pharmaceuticals	28.50%
TVGN Tevogen Bio	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	250	41.10 million	38.89 million	Not Optionable
ADCT ADC Therapeutics	310	99.18 million	92.73 million	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	44.15 million	Optionable
TVGN Tevogen Bio	3	183.89 million	75.97 million	N/A

ACHL, TVGN, ADCT, and CRVS Headlines

Recent News About These Companies

Tevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapie

June 1 at 10:47 PM | nl.investing.com

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Drop in Short Interest

June 1 at 4:04 AM | marketbeat.com

Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies

May 30 at 11:20 AM | quiverquant.com

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30 at 11:01 AM | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Earns Buy Rating from D. Boral Capital

May 29, 2025 | americanbankingnews.com

Tevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral Capital

May 28, 2025 | marketbeat.com

Tevogen Peports Plans to Increase the Target Population for TVGN 489

May 26, 2025 | msn.com

Tevogen expands target for COVID treatment to seniors

May 24, 2025 | investing.com

Tevogen Bio Inc: Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to ...

May 24, 2025 | finanznachrichten.de

Tevogen breidt doelgroep voor COVID-behandeling uit naar 65-plussers

May 23, 2025 | nl.investing.com

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

May 23, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. to Provide Key Updates Ahead of Annual Meeting on June 23, 2025

May 22, 2025 | quiverquant.com

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

May 22, 2025 | globenewswire.com

D. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)

May 14, 2025 | marketbeat.com

Tevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical Competition

May 13, 2025 | nasdaq.com

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

May 12, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing Facility

May 2, 2025 | nasdaq.com

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

May 2, 2025 | globenewswire.com

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

April 30, 2025 | uk.finance.yahoo.com

Why Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Up 5.60%

April 30, 2025 | aaii.com

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

April 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHL, TVGN, ADCT, and CRVS Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

$1.48 0.00 (0.00%)

As of 03/26/2025

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

ADC Therapeutics NYSE:ADCT

$3.10 +0.33 (+11.91%)

Closing price 05/30/2025 03:59 PM Eastern

Extended Trading

$3.09 -0.01 (-0.32%)

As of 03:59 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Corvus Pharmaceuticals NASDAQ:CRVS

$3.80 0.00 (0.00%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.78 -0.02 (-0.53%)

As of 03:59 AM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Tevogen Bio NASDAQ:TVGN

$1.28 -0.06 (-4.10%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.29 +0.01 (+0.39%)

As of 05:40 AM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time